Table 2– Effect of bosentan on 5 weeks echocardiographic parameters
ShamMIBos100Bos200
Cardiac output mL·min−1140±5120±11119±13114±7
LV wall motion abnormality %045±4#48±3#42±5#
LV wall motion score index1.00±01.96±0.05#2.00±0.07#1.87±0.07#
LV end-diastolic dimension mm7.6±0.210.9±0.2#10.9±0.2#11.2±0.2#
LV end-systolic dimension mm3.7±0.29.3±0.2#9.3±0.3#9.5±0.3#
LV end-diastolic area mm248.3±2.291.1±2.6#94.6±4.7#96.7±4.1#
LV end-systolic area mm216.0±1.462.4±2.9#68.5±4.7#65.3±3.6#
RVDd mm3.5±0.13.5±0.13.6±0.23.6±0.1
RVET ms83.4±2.583.6±2.986.4±1.880.7±2.3
TVc-o97.1±4.1120.1±5.1**127.9±8.1**113.9±5.4
  • Data are presented as mean±sem. MI: myocardial infarction; Bos100: bosentan 100 mg·kg−1·day−1; Bos200: bosentan 200 mg·kg−1·day−1; LV: left ventricular; RVDd: right ventricular end-diastolic dimension; RVET: right ventricular ejection time; TVc-o: tricuspid valve closing to opening. **p<0.01 versus sham; #: p<0.0001 versus sham.